Erik Amble
Founder, Chairman & Managing Partner @ Neomed Management
Oslo, Norway
Erik Amble is a Series C investor at Neomed Management in Oslo focused on Medical Device and Health Care. Erik Amble is the current Founder, Chairman and Managing Partner of Neomed Management. He previously worked at NeoMed AS as a Chairman. Erik Amble attended Stanford Graduate School of Business.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries Erik Amble invests in
Stages Erik Amble invests in
Countries Erik Amble invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical Device 4 (36%)
- Health Care 3 (27%)
- Medical 2 (18%)
- Biotechnology 2 (18%)
- Manufacturing 2 (18%)
Stage
- Series C 3 (27%)
- Series B 2 (18%)
- Venture - Series Unknown 2 (18%)
- Series A 1 (9%)
- Funding Round 1 (9%)
Country
- United States 2 (18%)
- Sweden 1 (9%)
- Germany 1 (9%)
- Switzerland 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $50M / Venture - Series Unknown / Feb 05, 2020 | ||
| Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder. | $14.5M / Series C / May 02, 2017 | ||
| Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder. | $38.5M / Series B / Dec 22, 2015 | ||
| JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $26.5M / Series C / Aug 07, 2015 | ||
| Sequana Medical is a Swiss medical device company providing implantable pump systems to manage fluid balance within the body. This system is designed to move excess fluid to the bladder, where it is passed naturally from the body through normal urination.Sequana Medical’s first product, the Alfapump System, is an innovative solution for themanagement of ascites. Ascites is a fluid that collects in the abdominal cavity in people with advanced liver disease, certain cancers, or congestive heart failure. Alfapump System was the first and only system for the automatic and continual removal of ascites.Sequana Medical was founded in 2006 and is based in Zurich, Switzerland. | $26.1M / Series C / Apr 25, 2014 | ||
| JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $10M / Series C / Apr 08, 2014 | ||
| Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder. | $32.6M / Series A / Mar 25, 2014 | ||
| InDex Pharmaceuticals AB is a clinical stage biopharmaceutical company building a leading immunotherapy franchise based on its TLR platform (toll-like receptors). It discovers and develops DIMS drugs (DNA-based immunomodulatory sequence) to treat diseases within a variety of therapeutic areas, including inflammation and cancer. | $20M / Venture - Series Unknown / Feb 25, 2014 | ||
| JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. The Company’s Trilogy™ Heart Valve System is a transcatheter aortic valve replacement (“TAVR”) system designed to treatpatients with symptomatic, severe aortic regurgitation (“AR”) and aortic stenosis (“AS”) in high surgical risk patients. The Trilogy System received CE Mark approval in May 2021, providing European physicians, for the first time, a device with true dual-disease treatment capabilities.JenaValve received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) to facilitate the review of ALIGN-AR, a pivotal trial in the U.S., as part of its premarket approval (“PMA”) application for the Trilogy Heart Valve System for the treatment of symptomatic, severe aortic regurgitation (AR) in high surgical risk patients. If approved, Trilogy would become the first and only TAVR system in the U.S. to be indicated for the treatment of AR patients.JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Additional information is available at www.jenavalve.com. US: CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. | $62.5M / Series C / Jul 23, 2013 | ||
| Vessix Vascular, Inc. (formerly known as Minnow Medical, Inc.). Vessix is a privately-held pre-revenue stage company developing novel radiofrequency balloon catheter technology. The Company's initial product, the ZCath® System, has a CE Mark for use in reducing plaque in peripheral leg arteries. | $23M / Series B / Aug 03, 2011 | ||
| See all 11 investments → | |||
Co-Investors
About Neomed Management
NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date. NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that address substantial market opportunities in the pharmaceutical, medical device and diagnostics industries. NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America. From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies. NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.
Neomed Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Erik Amble
Founder, Chairman & Managing Partner
|
|||
Thomas Goebel
Principal
|
|||
Vincent Ossipow
Partner
|
|||
Claudio Nessi
Partner
|
|||
Line B. Westlund
Office Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Erik Amble invest in?
Erik Amble invests primarily in Medical Device, Health Care and Medical startups, most often at Series C and Series B stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Erik Amble?
Public channels for Erik Amble include LinkedIn and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Erik Amble last invest?
The most recent investment recorded for Erik Amble closed in Feb 2020. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
